CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy. 

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 03, 2019

News & Publications

previousnext
Surgery, Breast-Conserving, Female
CTD²
January 15, 2020

Dissemination is an essential early step in metastasis but its molecular basis remains incompletely understood. To define the essential targetable effectors of this process, we developed a 3D mammary epithelial culture model, in which dissemination is induced by overexpression of the...

Proposed model of ST-mediated transformation
CTD²
January 08, 2020

Alterations involving serine-threonine phosphatase PP2A subunits occur in a range of human cancers and partial loss of PP2A function contributes to cell transformation. Displacement of regulatory B subunits by the SV40 Small T antigen (ST) or mutation/deletion of PP2A subunits alters the...

Experimental settings and reagents used in the experimental pipelines underlying the two compared data sets.
CTD²
December 20, 2019

Genome-scale CRISPR-Cas9 viability screens performed in cancer cell lines provide a systematic approach to identify cancer dependencies and new therapeutic targets. As multiple large-scale screens become available, a formal assessment of the reproducibility of these experiments becomes necessary...

Antibody-dependent cell-mediated cytotoxicity
CTD²
December 19, 2019

Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of natural killer (NK) cells mediated by therapeutic monoclonal antibodies (mAbs). This process is facilitated by the Fc receptor CD16a on human NK cells. CD16a appears to be the only activating receptor on NK cells...

Brain Cancer Regions
CTD²
December 05, 2019

The mechanistic target of rapamycin (mTOR) signaling is dysregulated prominently in human cancers including glioblastoma, suggesting mTOR as a robust target for therapy. Inhibitors of mTOR have had limited success clinically however, in part because their mechanism of action is cytostatic rather...

O
O
O
O
O